Nektar Therapeutics (NASDAQ:NKTR) CFO Gil M. Labrucherie sold 120,000 shares of Nektar Therapeutics stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $24.45, for a total transaction of $2,934,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Nektar Therapeutics (NKTR) traded down 1.09% during trading on Tuesday, reaching $24.50. 1,342,355 shares of the company’s stock traded hands. The company has a 50 day moving average price of $21.17 and a 200-day moving average price of $20.34. The stock’s market cap is $3.83 billion. Nektar Therapeutics has a one year low of $11.41 and a one year high of $24.93.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The firm had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. During the same quarter in the prior year, the business posted ($0.36) EPS. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, equities research analysts expect that Nektar Therapeutics will post ($0.98) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) CFO Sells $2,934,000.00 in Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/03/nektar-therapeutics-nktr-cfo-sells-2934000-00-in-stock.html.

Several equities research analysts recently issued reports on the stock. HC Wainwright initiated coverage on shares of Nektar Therapeutics in a report on Monday, August 7th. They issued a “buy” rating and a $31.00 target price on the stock. BidaskClub raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a report on Monday, June 26th. Jefferies Group LLC reissued a “buy” rating and set a $23.00 price target on shares of Nektar Therapeutics in a report on Friday, August 18th. Finally, Mizuho assumed coverage on Nektar Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $26.80.

Several hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Nektar Therapeutics by 14.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 692 shares during the period. LS Investment Advisors LLC increased its stake in shares of Nektar Therapeutics by 8.8% in the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 535 shares in the last quarter. Flinton Capital Management LLC increased its stake in shares of Nektar Therapeutics by 75.7% in the 2nd quarter. Flinton Capital Management LLC now owns 7,872 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 3,392 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Nektar Therapeutics by 21.8% in the 1st quarter. Bank of Montreal Can now owns 8,195 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 1,464 shares in the last quarter. Finally, Miles Capital Inc. acquired a new position in Nektar Therapeutics in the 1st quarter worth about $204,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.